Connect your AI

Janux Therapeutics JANX Stock-Based Comp

Stock-Based Comp at other companies

Johnson & JohnsonJNJ

$300M+4.2%

AmgenAMGN

$75M-11.8%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

XencorXNCR

$9.56M-21.7%

AbbVieABBV

$444M+8.3%

Vor BiopharmaVOR

$8.87M+359%

Other financials

Income statement

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

Market cap$892.81M-36.1%

Enterprise value$862.55M-35.9%

P/S65×-84.6×

Profitability

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Janux Therapeutics's stock-based comp?: Janux Therapeutics (JANX) reported stock-based comp of $9.27M in Q1 2026.
How has Janux Therapeutics's stock-based comp changed year-over-year?: Janux Therapeutics's stock-based comp decreased by 13.4% year-over-year, from $10.7M to $9.27M.
What is the long-term trend for Janux Therapeutics's stock-based comp?: Over 4 years (2021 to 2025), Janux Therapeutics's stock-based comp has grown at a 55.3% compound annual growth rate (CAGR), from $6.91M to $40.22M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.